Palisade Bio, Inc. (NASDAQ:PALI) Given Consensus Rating of “Buy” by Analysts

Palisade Bio, Inc. (NASDAQ:PALI) has been assigned a consensus recommendation of “Buy” from the ten analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $9.00.

PALI has been the subject of a number of recent research reports. LADENBURG THALM/SH SH upgraded Palisade Bio to a “strong-buy” rating in a research report on Thursday, June 25th. Wall Street Zen upgraded shares of Palisade Bio from a “sell” rating to a “hold” rating in a research report on Saturday, July 25th. Oppenheimer started coverage on shares of Palisade Bio in a research note on Thursday, July 23rd. They set an “outperform” rating and a $8.00 price target on the stock. HC Wainwright restated a “buy” rating and issued a $2.00 price objective on shares of Palisade Bio in a report on Tuesday, June 30th. Finally, Weiss Ratings cut shares of Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, July 14th.

Insider Buying and Selling

In other Palisade Bio news, Director Robert Baltera purchased 30,000 shares of the stock in a transaction on Tuesday, July 7th. The stock was acquired at an average cost of $2.03 per share, with a total value of $60,900.00. Following the completion of the purchase, the director directly owned 416,904 shares of the company’s stock, valued at approximately $846,315.12. This trade represents a 7.75% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO John Finley sold 146,798 shares of the business’s stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $2.07, for a total transaction of $303,871.86. Following the completion of the sale, the chief executive officer directly owned 217,555 shares of the company’s stock, valued at $450,338.85. This represents a 40.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have acquired a total of 125,000 shares of company stock worth $250,100 in the last 90 days. 0.07% of the stock is owned by company insiders.

Institutional Investors Weigh In On Palisade Bio

Several institutional investors have recently bought and sold shares of the stock. WINTON GROUP Ltd grew its position in Palisade Bio by 180.2% during the 2nd quarter. WINTON GROUP Ltd now owns 32,227 shares of the company’s stock worth $67,000 after acquiring an additional 20,727 shares during the last quarter. PCG Wealth Advisors LLC bought a new stake in Palisade Bio in the second quarter valued at approximately $86,000. Susquehanna International Group LLP bought a new stake in Palisade Bio in the second quarter valued at approximately $65,000. Two Sigma Securities LLC purchased a new stake in shares of Palisade Bio during the second quarter valued at approximately $57,000. Finally, Wellington Management Group LLP boosted its stake in shares of Palisade Bio by 27.5% during the second quarter. Wellington Management Group LLP now owns 3,703,936 shares of the company’s stock valued at $7,741,000 after purchasing an additional 799,025 shares during the period. 11.79% of the stock is currently owned by hedge funds and other institutional investors.

Palisade Bio Price Performance

Shares of NASDAQ:PALI opened at $2.06 on Tuesday. The company’s fifty day moving average price is $2.03 and its 200-day moving average price is $1.97. The firm has a market capitalization of $359.00 million, a price-to-earnings ratio of -4.29 and a beta of 1.53. Palisade Bio has a one year low of $0.55 and a one year high of $2.86.

Palisade Bio (NASDAQ:PALI) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.50 million. As a group, equities research analysts expect that Palisade Bio will post -0.23 EPS for the current year.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.